Drugs / TMC649128
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01391117 | Jun → Nov 2011 | hepatitis C virus infection | Tibotec BVBA | Terminated | Missed primary |
| Phase 1 | NCT01288677 | Jan → Jun 2011 | — | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-11-15 | Medivir | Results Key news from the ongoing Capital Markets Day medivir.com ↗
However the antiviral activity failed to meet the target product profile and therefore the clinical development has now been discontinued. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-11-15 | Medivir | Key news from the ongoing Capital Markets Day medivir.com ↗ |
| 2011-06-22 | Medivir | TMC649128 enters Phase Ib Trial in Patients Chronically Infected with Genotype-1 Hepatitis C Virus medivir.com ↗ |
| 2011-02-10 | Medivir | Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128 medivir.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMC649128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01391117 ↗ |
| Action | Inhibit | “TMC649128 is a nucleoside inhibitor (NI) of hepatitis C virus (HCV) polymerase” NCT01391117 ↗ |
| Modality | Small molecule | “TMC649128 is a nucleoside inhibitor (NI) of hepatitis C virus (HCV) polymerase” NCT01391117 ↗ |
| Route | Oral | “single oral doses of TMC649128” NCT01288677 ↗ |